CytoDyn Inc. | Income Statement
Fiscal year is June-May. All values USD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
352.40
360.60
361.60
366.40
356.10
Gross Income
352.40
360.60
361.60
366.40
356.10
SG&A Expense
7,760.30
19,235.90
20,813.90
26,964.30
45,563.20
EBIT
8,112.70
19,596.50
21,175.50
27,330.70
45,919.30
Unusual Expense
183.90
838.60
135.20
2,164.50
1,690.90
Non Operating Income/Expense
-
-
-
540.30
-
Interest Expense
4,510.40
4,655.10
4,671.20
72.40
5,924.90
Pretax Income
12,431.40
25,088.10
25,703.60
25,763.80
50,149.70
Consolidated Net Income
12,431.40
25,088.10
25,703.60
25,763.80
50,149.70
Net Income
12,431.40
25,088.10
25,703.60
25,763.80
50,149.70
Net Income After Extraordinaries
12,431.40
25,088.10
25,703.60
25,763.80
50,149.70
Net Income Available to Common
12,431.40
25,088.10
25,703.60
25,763.80
50,149.70
EPS (Basic)
0.27
0.43
0.27
0.19
0.29
Basic Shares Outstanding
46,900.60
58,375.60
95,437.60
138,004.50
174,885.40
EPS (Diluted)
0.27
0.43
0.27
0.19
0.29
Diluted Shares Outstanding
46,900.60
58,375.60
95,437.60
138,004.50
174,885.40
EBITDA
7,760.30
19,236.00
20,813.90
26,964.30
45,563.20
Non-Operating Interest Income
7.80
2.20
7.90
15.20
3.60
About CytoDyn
View Profile
